We are live on ! Find out more
APLS

Apellis Pharmaceuticals
APLS

Delisted

APLS was delisted on the 13th of May, 2026.

Back to rankings

1 hedge funds and large institutions have $10.2K invested in Apellis Pharmaceuticals in 2026 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 279 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 323 → 1 (-322)

100% less funds holding in top 10

Funds holding in top 10: 6 → 0 (-6)

100% less capital invested

Capital invested by funds: $5.56B → $10.2K (-$5.56B)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 279

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

109.78% less ownership

Funds ownership: 109.78% → 0% (-110%)

Holders
1
Holders Change
-322
Holders Change %
-99.69%
% of All Funds
0.01%
Holding in Top 10
–
Holding in Top 10 Change
-6
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
1
Closed
279
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$545M
2
ACA
Avoro Capital Advisors
New York
-$492M
3
Morgan Stanley
Morgan Stanley
New York
-$404M
4
State Street
State Street
Massachusetts
-$275M
5
UBS Group
UBS Group
Switzerland
-$250M
Name Holding Trade Value Shares
Change 		Change in
Stake
ProShare Advisors
201
ProShare Advisors
Maryland
– -$274K -6,809 Closed
BFIM
202
Beese Fulmer Investment Management
Ohio
– -$271K -6,748 Closed
Mirae Asset Global Investments
203
Mirae Asset Global Investments
South Korea
– -$268K -6,668 Closed
MIM
204
MetLife Investment Management
New Jersey
– -$267K -6,633 Closed
Walleye Trading
205
Walleye Trading
New York
– -$266K -6,602 Closed
QT
206
Quantbot Technologies
New York
– -$264K -6,567 Closed
DnB Asset Management
207
DnB Asset Management
Norway
– -$249K -6,184 Closed
FCM
208
Farallon Capital Management
California
– -$241K -6,000 Closed
YCM
209
Yakira Capital Management
Connecticut
– -$241K -6,000 Closed
MG
210
Marex Group
– -$238K -5,919 Closed
BCI
211
Brinker Capital Investments
Pennsylvania
– -$237K -5,899 Closed
M1FG
212
Mach-1 Financial Group
Arkansas
– -$228K -5,672 Closed
URS
213
Utah Retirement Systems
Utah
– -$225K -5,600 Closed
SAS
214
Stelac Advisory Services
New York
– -$222K -5,520 Closed
SLAM
215
Swiss Life Asset Management
– -$217K -5,384 Closed
T. Rowe Price Investment Management
216
T. Rowe Price Investment Management
Maryland
– -$208K -5,162 Closed
Ensign Peak Advisors
217
Ensign Peak Advisors
Utah
– -$191K -4,747 Closed
Walleye Capital
218
Walleye Capital
New York
– -$132K -3,290 Closed
Jones Financial Companies
219
Jones Financial Companies
Missouri
– -$50.6K -2,984 Closed
GFM
220
GF Fund Management
China
– -$114K -2,841 Closed
HFS
221
Hantz Financial Services
Michigan
– -$114K -2,836 Closed
Simplex Trading
222
Simplex Trading
Illinois
– -$110K -2,735 Closed
Osaic Holdings
223
Osaic Holdings
Arizona
– -$105K -2,615 Closed
SO
224
STRS Ohio
Ohio
– -$104K -2,579 Closed
KBC Group
225
KBC Group
Belgium
– -$93K -2,313 Closed
7 8
9
10 11

APLS Hedge Fund Activity: Q2 2026 in Review

1 of the 8,153 institutional investors tracked by Wall St. Rank reported a position in Apellis Pharmaceuticals (APLS) for Q2 2026, worth a combined $10.2K — down 100% from $5.56B a quarter earlier.

Sellers outnumbered buyers: 279 funds closed out of APLS and 0 opened new positions — a net loss of 279 holders — while 1 trimmed existing stakes and 0 added.

The largest seller was BlackRock, exiting entirely with an estimated $545M sold.

  • 1 institutional investor held Apellis Pharmaceuticals (APLS) as of Q2 2026, down from 323 in Q1 2026.
  • Funds reported $10.2K of Apellis Pharmaceuticals stock for Q2 2026, down 100% quarter-over-quarter.
  • 0 funds opened new Apellis Pharmaceuticals positions in Q2 2026 and 279 closed out, a net change of -279 holders.
  • The largest Apellis Pharmaceuticals seller in Q2 2026 was BlackRock, an estimated $545M sold.

Based on aggregated 13F filings for Q2 2026.